https://www.selleckchem.com/pr....oducts/tj-m2010-5.ht
ty building; few impacted health. Recommending common early phase logic model pathways may facilitate downstream success.Introduction Needle and syringe programs and opioid agonist therapy are essential for harm reduction among people who inject drugs. Few studies assess their combined potential in preventing hepatitis C virus infection. No studies have assessed whether they perform similarly among individuals at risk of primary and recurrent infection. This study aimed to estimate the rates of hepatitis C virus acquisition according